Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Plavix)
11,523 results
  • Meta-Analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients with Acute Coronary Syndrome. [Journal Article]
  • JCJ Cardiovasc Pharmacol 2016 Nov 29
  • Zhang L, Lu J, … Dong Y
  • CONCLUSIONS: Based on this meta-analysis, newer P2Y12 inhibitors were significantly more effective than clopidogrel in the events of MI and cardiovascular death in patients with acute coronary syndrome, although the incidence of TIMI-defined bleeding was higher compared with clopidogrel.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
  • Mortality in patients who discontinue low-dose acetylsalicylic acid therapy after upper gastrointestinal bleeding. [Journal Article]
  • PDPharmacoepidemiol Drug Saf 2016 Dec 06
  • González-Pérez A, Sáez ME, … García Rodríguez LA
  • CONCLUSIONS: ASA therapy for secondary prevention should continue after UGIB because the risk of death tends to increase when ASA is stopped. However, a significantly increased risk was not found in these patients, likely owing to the relatively small number of ASA users and deaths that occurred during follow-up. Further studies with larger samples sizes are needed to confirm these findings among UGIB survivors taking ASA at the time of UGIB. Copyright © 2016 John Wiley & Sons, Ltd.
New Search Next